ERBB2 and neoplasm: We previously demonstrated that our combination immunotherapy strategy, which couples oncolytic adenoviral immunotherapy (CAd)10 with clinically tested HER2-specific CAR T-cells (HER2.CART)11,12, mediates significant anti-tumor effects against multiple solid tumors13.